ISSN (Online): 2321-3418
server-injected
Medical Sciences and Pharmacy
Open Access

Association of Silent Information Regulator 1 (Sirt1) Gene Polymorphism with the Pathogenesis of Diabetic Nephropathy

, , ,
DOI: 10.18535/ijsrm/v10i10.mp02· Pages: 706-720· Vol. 10, No. 10, (2022)· Published: October 18, 2022
PDF
Views: 520 PDF downloads: 175

Abstract

Introduction: Diabetic nephropathy (DN) is one of the major microvascular complications of diabetes mellitus. Patients with diabetic nephropathy are at a higher risk of morbidity and mortality than those without nephropathy. In this case, early diagnosis and prevention of DM are crucial. SIRT1, which is among the seven members of sirtuins, is recognized as an important element in the pathogenesis of type 2 diabetes, therefore it has several actions in the diabetic nephropathy that will be further discussed in this study. This study will analyse the relationship between SIRT1 gene polymorphism and serum sirt1 in the pathogenesis of diabetic nephropathy.

Aim of the study: evaluation of the association of Silent Information Regulator1 (SIRT1) gene polymorphism and serum SIRT1 protein with type 2 diabetic patients and their role in the pathogenesis of diabetic nephropathy.

Subjects and Methods: This study was carried out on 120 subjects with matched age and sex. They were divided into 3 groups: (Group 1: 40 diabetic nephropathy patients, Group 2: 40 diabetic patients without diabetic nephropathy, Group 3: 40 healthy control subjects ) to discuss the association of sirt1 gene polymorphism and the pathogenesis of diabetic nephropathy.

Results: The mean levels of the serum SIRT1 protein was significantly increasing in the diabetic nephropathy group than the diabetics without diabetic nephropathy and the controls, while it was not significant between the diabetics without DN and the control group.

Conclusion: Basedon this study, SIRT1 gene polymorphism is a significant factor in the development and progression of DN.

Keywords

Diabetic Nephropathy – SIRT1 gene – Pathogenesis – Kidney

References

  1. Kumar A., Singh UK. (2013). Molecular mechanisms in the pathogenesis of diabetic nephropathy: an update. Vascul Pharmacol. 2013 Apr;58(4):259-71. doi: 10.1016/j.vph.2013.01.001. Epub 2013 Jan 11. PMID: 23313806.DOI ↗Google Scholar ↗
  2. Donate-Correa J, Martín-Núñez E, Muros-de-Fuentes M, et al. (2015). Inflammatory cytokines in diabetic nephropathy. J Diabetes Res. 2015;2015:948417. doi: 10.1155/2015/948417. Epub 2015 Feb 15. PMID: 25785280; PMCID: PMC4345080.DOI ↗Google Scholar ↗
  3. Afkarian M, Sachs MC, Kestenbaum B, et al.,(2013). Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013 Feb;24(2):302-8. doi: 10.1681/ASN.2012070718. Epub 2013 Jan 29. PMID: 23362314; PMCID: PMC3559486.DOI ↗Google Scholar ↗
  4. Zhang L, et al. (2016): Prevalence of chronic kidney disease and associated factors in Chinese individuals with type 2 diabetes: Cross-sectional study. J Diabetes Complications. 2016 Jul;30(5):803-10.doi:10.1016/j.jdiacomp.2016.03.020. Epub 2016 Mar 17. PMID: 27068269.DOI ↗Google Scholar ↗
  5. Kume S, Uzu T, Kashiwagi A. et al. (2010): SIRT1, a calorie restriction mimetic, in a new therapeutic approach for type 2 diabetes mellitus and diabetic vascular complications. Endocr Metab Immune Disord Drug Targets; 10: 16-24Google Scholar ↗
  6. Polak-Jonkisz D, Laszki-Szczachor K, Rehan L. et al. (2013): Nephroprotective action of sirtuin 1 (SIRT1). J Physiol Biochem; 69: 957-961Google Scholar ↗
  7. Maeda S, Koya D, Araki S. et al. (2011): Association between single nucleotide polymorphisms within genes encoding sirtuin families and diabetic nephropathy in Japanese subjects with type 2 diabetes. Clin Exp Nephrol; 15: 381-390Google Scholar ↗
  8. Young BA, Maynard C, Boyko EJ., et al., (2003): Racial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of veterans. Diabetes Care 26 (8):2392–2399Google Scholar ↗
  9. Haraldsson B, Nystrom J, Deen WM, et al., (2008): Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev 88 (2):451–487Google Scholar ↗
  10. Gnudi L, Gentile G, Ruggenenti P, et al., (2016): The patient with diabetes mellitus. In: Turner N, Lamiere N, Goldsmith DJ, Wineearls CG, Himmelfarb J, Remuzzi G (eds) Oxford textbook of clinical nephrology, vol 2. Oxford University Press, Oxford, pp 1199–1247Google Scholar ↗
  11. Huang L. and Khardori R. (2017): Pathogenesis of Diabetic Nephropathy. In: Managing Diabetic Nephropathies in Clinical Practice. Adis, Cham. https://doi.org/10.1007/978-3-319-08873-0_2DOI ↗Google Scholar ↗
  12. Amin R, Turner C, van Aken S, et al., (2005): The relationship between microalbuminuria and glomerular filtration rate in young type 1 diabetic subjects: The Oxford Regional Prospective Study. Kidney Int.;68:1740–9.Google Scholar ↗
  13. Premaratne E, Verma S, Ekinci EI, et al., (2015): The impact of hyperfiltration on the diabetic kidney. Diabetes Metab.;41:5–17.Google Scholar ↗
  14. Singh AK, Mo W, Dunea G, et al., (1998): Effect of glycated proteins on the matrix of glomerular epithelial cells. J Am Soc Nephrol.;9:802–10.Google Scholar ↗
  15. Reidy K, Kang HM, Hostetter T, et al., (2014): Molecular mechanisms of diabetic kidney disease. J Clin Invest. ;124: 2333–40.Google Scholar ↗
  16. Tervaert TW, Mooyaart AL, Amann K, et al., (2010): Pathologic classification of diabetic nephropathy. J Am Soc Nephrol.;21:556–3.Google Scholar ↗
  17. Romagnani P. and Remuzzi G. (2013): Renal progenitors in non-diabetic and diabetic nephropathies. Trends Endocrinol Metab.;24:13–20.Google Scholar ↗
  18. Furuta T, Saito T, Ootaka T, et al. (1993): The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis.;21:480–5.Google Scholar ↗
  19. Nguyen D, Ping F, Mu W, et al., (2006): Macrophage accumulation in human progressive diabetic nephropathy. Nephrology (Carlton).;11:226–31.Google Scholar ↗
  20. Yonemoto S, Machiguchi T, Nomura K, et al., (2006): Correlations of tissue macrophages and cytoskeletal protein expression with renal fibrosis in patients with diabetes mellitus. Clin Exp Nephrol.;10:186–92.Google Scholar ↗
  21. Ha HJ, Yu MR, Choi YJ, et al., (2002): Role of high glucose-induced nuclear factor-kappa B activation in monocyte chemoattractant protein-1 expression by mesangial cells. J Am Soc Nephrol.;13:894–902Google Scholar ↗
  22. Chen JS, Lee HS, Jin JS, et al. (2004): Attenuation of mouse mesangial cell contractility by high glucose and mannitol: Involvement of protein kinase C and focal adhesion kinase. J Biomed Sci.;11:142–51.Google Scholar ↗
  23. Ruiz-Ortega M, Lorenzo O, Ruperez M, et al., (2001): Renin-angiotensin system and renal damage: emerging data on angiotensin II as a proinflammatory mediator. Contrib Nephrol.;135:123–37.Google Scholar ↗
  24. Nakagawa T, Tanabe K, Croker BP, et al., (2011): Endothelial dysfunction as a potential contributor in diabetic nephropathy. Nat Rev Nephrol.;7:36–44.Google Scholar ↗
  25. Rudberg S. and Osterby R. (1997): Decreasing glomerular filtration rate – an indicator of more advanced diabetic glomerulopathy in the early course of microalbuminuria in IDDM adolescents? Nephrol Dial Transplant.;12:1149–54.Google Scholar ↗
  26. Nelson RG, Knowler WC, McCance DR, et al., (1993): Determinants of end-stage renal disease in Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus and proteinuria. Diabetologia.;36:1087–93.Google Scholar ↗
  27. Deckert T, Feldt-Rasmussen B, BorchJohnsen K, et al.,(1989): Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 32(4):219–226Google Scholar ↗
  28. Berhane AM, Weil EJ, Knowler WC, et al., (2011): Albuminuria and estimated glomerular filtration rate as predictors of diabetic end-stage renal disease and death. Clin J Am Soc Nephrol 6(10):2444–2451Google Scholar ↗
  29. Gnudi L, Coward RJ, Long DA, et al., (2016): Diabetic nephropathy: perspective on novel molecular mechanisms. Trends Endocrinol Metab 27 (11):820–830Google Scholar ↗
  30. Gizem D and Tiago FO. (2013): SIRT1 and SIRT2: emerging targets in neurodegenration. EMBO Mol Med.;5:344 – 352.Google Scholar ↗
  31. Guan, Y., and Hao, C.M. (2015, 10 13): SIRT1 and Kidney Function. Kidney Diseases, 1(4), 258-265.Google Scholar ↗
  32. Haigis MC and Sinclair DA. (2010): Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol.;5:253–295Google Scholar ↗
  33. Wakino S, Hasegawa K, Itoh H, et al., (2015): Sirtuin and metabolic kidney disease. Kidney Int, Epub ahead of print.Google Scholar ↗
  34. Dong Y., Liu, Xiao, et al., (2014): Renal protective effect of sirtuin 1. Journal of Diabetes Research, 2014. Hindawi Publishing Corporation.Google Scholar ↗
  35. Haigis M. C. and Guarente L. P., (2006): “Mammalian sirtuins— emerging roles in physiology, aging, and calorie restriction,”Genes and Development, vol.20, no.21, pp.2913–2921.Google Scholar ↗
  36. Kong L., Wu, H., Zhou W., et al.,(2015, 1 12): Sirtuin 1: A target for kidney diseases. Molecular Medicine, 21, 87-97.Google Scholar ↗
  37. Kitada, M., Kume, S. & Koya, D., et al., (2014): Role of sirtuins in kidney disease. Curr. Opin. Nephrol. Hypertens. 23,Google Scholar ↗
  38. Turkmen k, Karagoz A, Kucuk A, et al., (2014): Sirtuins as novel players in the pathogenesis of diabetes mellitus. World J Diabetes.; 5(6):894- 900Google Scholar ↗
  39. Song YS, Lee SK, Jang YJ, et al., (2013): Association between low SIRT1 expression in visceral and subcutaneous adipose tissues and metabolic abnormalities in women with obesity and type 2 diabetes. Diabetes Res ClinPract. 101: 341-348.Google Scholar ↗
  40. Rahman S and Islam R (2011): Mammalian Sirt1: insights on its biological functions. Cell Commun Signal.; 9: 11.Google Scholar ↗
  41. Gross JL, de Azevedo MJ, Silveiro SP, et al., (2005): Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 28(1):164–176Google Scholar ↗
  42. Coresh J, Selvin E, Stevens LA., et al. (2007): Prevalence of chronic kidney disease in the United States. JAMA; 298: 2038-2047Google Scholar ↗
  43. Gok O, Karaali Z, Ergen A, et al.,(2019 JUN): Serum sirtuin 1 protein as a potential biomarker for type 2 diabetes: Increased expression of sirtuin 1 and the correlation with microRNAs. J Res Med Sci. 25;24:56. doi: 10.4103/jrms.JRMS_921_18. PMID: 31333735; PMCID: PMC6611179.DOI ↗Google Scholar ↗
  44. Tang, K., Sun M., Shen, J., et al., (2017): Transcriptional Coactivator p300 and Silent Information Regulator 1 (SIRT1) Gene Polymorphism Associated with Diabetic Kidney Disease in a Chinese Cohort. Experimental and Clinical Endocrinology & Diabetes, 125.Google Scholar ↗
  45. Zhao, Y., Wei, J., Hou, X., et al., (2017, 12 1): SIRT1 rs10823108 and FOXO1 rs17446614 responsible for genetic susceptibility to diabetic nephropathy. Scientific Reports, 7(1)Google Scholar ↗
  46. -Google Scholar ↗
Author details
Ola Abdelmoneim Elkholy
Clinical pathologist in General authority of health, Cairo, Egypt
✉ Corresponding Author
ORCID ↗
👤 View Profile →
Gihan Farouk Attia
Clinical Pathology Department, Faculty of Medicine, Tanta University, Tanta,Egypt
👤 View Profile →
Wesam Salah Ibrahim
Clinical Pathology Department, Faculty of Medicine, Tanta University, Tanta,Egypt
👤 View Profile →
Amal Selim
Internal Medicine Department, Faculty of Medicine, Tanta University, Tanta,Egypt
👤 View Profile →